Published in final edited form as:

Anal Biochem. 2011 January 1; 408(1): 136–146. doi:10.1016/j.ab.2010.08.031.

Label-free LC-MS/MS Analysis with Automated Phosphopeptide Enrichment Reveals Dynamic Human Milk Protein Phosphorylation during Lactation

John W. Froehlich¹, Caroline S. Chu¹, Ning Tang², Keith Waddell², Rudolf Grimm², and Carlito B. Lebrilla^{1,3}

¹UC Davis Dept. of Chemistry

²Agilent Technologies

³UC Davis Dept. of Biochemistry and Molecular Medicine

Abstract

Protein phosphorylation is a critical post-translational modification that affects cell-cell signaling and protein function. However, quantifying the relative, site-specific changes of phosphorylation occupancies remain a major issue. An on-line enrichment of phosphopeptides using titanium dioxide incorporated in a microchip liquid chromatography device was used to analyze trypsin-digested human milk proteins with mass spectrometry. The method was validated with standards, and utilized to determine the dynamic behavior of protein phosphorylation in human milk from the first month of lactation. Alpha-casein, beta-casein, osteopontin, and chordin-like protein 2 phosphoproteins were shown to vary during this lactation time in an independent manner. In addition, changes in specific regions of these phosphoproteins were found to vary independently. Novel phosphorylation sites were discovered for chordin-like protein 2, alpha-lactalbumin, beta 1-4 galactosyl transferase and poly-Ig receptor. Coefficients of variation for the quantitation were comparable to other contemporary approaches using isotopically labeled peptides, with a median value of 11% for all phosphopeptide occupancies quantified.

Keywords

Milk; Phosphoprotein; Quantification; Label-Free; Proteomics

INTRODUCTION

Phosphorylation, which has been shown to affect protein function and cell-cell signaling, is a widespread and critical post-translational modification (PTM). Determination of protein phosphorylation by mass spectrometry is challenging for a number of reasons, a few of which include the relative lability of the phosphate group, substoichiometric quantities of the PTM, and ion suppression of phosphopeptides in the presence of peptides which are also generated by sample preparation. There have been a number of solutions to the second and third of these challenges that mainly utilize chromatographic enrichment of phosphopeptides.

© 2010 Elsevier Inc. All rights reserved.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Phosphopeptide or phosphoprotein enrichment has been achieved through immobilized metal affinity chromatography, strong cation or anion exchange chromatography, titanium dioxide enrichment, and antibodies. Recently, a chip-based platform has been developed for automated phosphopeptide enrichment and analysis by nLC-MS/MS.¹ This platform combines the advantages of selective, reproducible, automated phosphopeptide enrichment with an integrated MS nanospray emitter that may be directly coupled to a variety of instruments. The present study utilizes this platform for the analysis of human milk phosphorylation during the first month of lactation.

An extensive abundance of glycosylated and phosphorylated milk proteins as well as a high abundance of the completely indigestible human milk oligosaccharides (HMO) combine to suggest that milk is much more than a nutrition source. Indeed, HMOs have been shown to possess a variety of biological roles, including selection of a healthy microbiota and functioning as receptor analogues for pathogenic bacteria.² Similarly, the protein fraction of human milk possesses a wide variety of bioactivities, including immunomodulatory, bacteriostatic, bacteriocidal, anti-inflammatory, and apoptotic activities.³ Human milk proteins also exhibit proteolytic⁴ and lipolytic activities.⁵ In addition, many milk proteins are resistant to digestion. This resistance, in concert with a developing neonatal digestive system, facilitates the survival of both fully intact and minimally degraded biologically active forms of milk proteins in the gastrointestinal tract (GIT) of the infant.⁶ These phenomena demonstrate that while the protein fraction of human milk presents a near perfect dietary balance of amino acids, it is by no means merely a source of amino acids. Instead, the emerging view is that milk is a highly functional food⁷ that influences bacterial colonization⁸, attunes neonatal immune response⁹, and promotes infant brain development¹⁰ via specific components present in the mixture. Quantitative changes in these specific components during lactation likely cause a change in the bioactivities that milk provides.

In fact, quantitative variations of these specific components during lactation could be driven by the development of the neonate. In particular, the nutritional needs, intestinal flora, and immune system of the neonate change as he/she grows. Milk has been shown to modulate each of these, for example the neonate's need for supplementary support of his/her immune system also diminishes as they grow. While the mother could potentially continue to express and secrete these immunological factors into milk after the neonate's own immune system has developed, this would represent a substantial physiological inefficiency. Instead, it appears the abundance of these components decrease as the need for them decreases. Similar changes for specific PTMs such as phosphorylation could also lend insight to what biological roles the PTMs support. The determination of quantitative changes in milk protein phosphorylation in this study is performed with these considerations in mind.

The majority of milk protein phosphorylation is present in a class of proteins known as caseins. In human milk from the first month of lactation, phosphorylated alpha- and beta-casein comprise approximately 10-30% of the total protein present¹¹. Kappa casein is extensively glycosylated and constitutes the remainder of the casein fraction. The caseins are critical to mineral transport and absorption within the infant's digestive system, and they complex with calcium phosphate to form the micelles present in milk. The phosphorylation sites of the caseins have been extensively characterized¹²⁻¹⁴ and further site determination of these well-studied phosphoproteins is not the goal herein. In the current study, a label-free method was developed to determine the changes in phosphorylation site occupancy during the first month of lactation. Quantitative changes in phosphorylation site occupancy for four milk phosphoproteins are reported, including alpha-casein, beta-casein, osteopontin (OPN), and chordin-like protein 2 (CHRD2).

MATERIALS AND METHODS

Materials

All water used was generated by milli-Q filtration, and was measured as 18 M Ω water. The phosphopeptide kit, containing the phosphochip and necessary elution and regeneration solutions was provided by Agilent Technologies Inc. (Santa Clara, CA). Sequencing grade, modified trypsin was purchased from Promega (Madison, WI). Formic acid (HPLC grade), acetic acid (HPLC grade), dithiothreitol, iodoacetamide and tris buffer were all purchased from Sigma-Aldrich (St. Louis, MO). Acetonitrile (Honeywell Burdick and Jackson) was purchased from VWR (West Chester, PA).

Samples

Samples were donated by a healthy individual donor. Milk was collected by manual expression and immediately frozen at -80 °C until ready for protein extraction. A thawed aliquot (250 μ L) of milk from a single donor from lactation days 2, 5, 10, 17, and 29 was adjusted to 1 mM sodium orthovanadate, and skimmed by centrifugation at 4 °C for 30 minutes. Skimmed milk was dialyzed against a solution of 25 mM NH₄HCO₃, 1 mM sodium orthovanadate pH=7.4 for 16 hours with 2 changes of dialysate.

Bulk Sample Protein Quantitation

Dialyzed milk samples were quantified via the Bradford method, using bovine serum albumin for the calibration curve.

Protein Digestion

Aliquots of 200 μ g of each sample were used for proteolysis. Samples were reduced with 3 μ L of 0.5 M dithiothreitol at 55 °C for 45 minutes. Alkylation was performed by the addition of 6 μ L of 450 mM iodoacetamide, followed by incubation in the dark at room temperature for 20 minutes. Samples were desalted using C₁₈ cartridges, and dried in vacuo.

nLC-MS/MS Conditions and Phosphopeptide Enrichment

Samples were reconstituted in 3% acetonitrile and analyzed using an Agilent 1200 series microwell-plate autosampler (maintained at 6.0 °C), capillary pump, nanopump, HPLC-Chip interface, and the Agilent 6520 qTOF LC-MS/MS system. The Phosphochip (G4240-62021) consists of a 40 nL “sandwiched” C₁₈-TiO₂-C₁₈ enrichment column and a 43 $\times$ 0.075 mm ID, 5 μ m C₁₈ analytical column. For sample loading, the capillary pump delivered 0.1% formic acid in 3.0% acetonitrile in water (v/v) isocratically at 3 μ L/min. Injection volume was 15 μ L for each sample. Technical triplicates were injected. A gradient was delivered at 0.3 μ L/min using A) 0.5% formic acid; 0.6% acetic acid in 3% acetonitrile in water (v/v) and B) 0.5% formic acid; 0.6% acetic acid in 90% acetonitrile in water (v/v). A 60.0 minute nanoLC gradient was run from 0%-35% B, 0.0-40.0 minutes; 35%-45% B, 40.0-45.0 minutes; 45%-90% B, 45.0-48.0 minutes, and held for 2.0 minutes at 100% B with an equilibration time of 10.0 minutes at 0% B. The drying gas temperature was set at 325 °C with a flow of 4.0 L/min (2.0 L nitrogen and 2.0 L dry grade compressed air). Precursor scan data was acquired in the positive ionization mode within a mass range of m/z 300-2000. Tandem mass spectra were acquired from m/z 50 to 3000. Variable collision voltages of -4.8 + 3.6 V/100 m/z were utilized for fragmentation. Mass correction was enabled for all precursor scan data using a reference mass of m/z 1221.991, an internal standard (ESI-TOF Tuning Mix G1969-85000, Agilent Technologies, Inc., Santa Clara, CA). Data analysis was performed using Spectrum Mill, MassHunter Qualitative Analysis Software B.01.03 Build 157, and Microsoft Excel 2007.

Database Searching

Deconvolution, deisotoping, data extraction, and database searching were performed using Spectrum Mill. After data processing, the swiss-prot database (sp. Homo Sapiens) was searched with the following parameters: peptide mass range 400-4500 Daltons. Carbamidation of cysteine residues was included as a constant modification. In addition, deamidation of asparagines, oxidation of methionines, and phosphorylation of serine, threonine, and tyrosine residues were also searched as variable modifications.

Peptide and Protein Validation

Peptides were validated in an automated fashion, using Spectrum Mill. Charge states of 5, 4, 3 and 2 were allowed, requiring scores of 10, 9, 8 and 7 respectively. All peptides also required a delta forward-reverse score of at least 3 and a minimum of 65% of the intensity of MS/MS spectra were required to be assigned for the assignment to be validated. Peptide and Phosphopeptide MS/MS spectra were automatically validated as above. Phosphopeptide assignments were also manually verified by inspection to determine the accuracy of the automated phosphorylation site assignments.

Protein identifications were also validated in an automated fashion. All proteins with a Spectrum Mill score above 25 and with at least two unique peptides were considered valid in this study.

Relative Phosphorylation Quantitation

A protein-specific normalization strategy was utilized as follows. First, all validated peptide signals for a given protein were summed and triplicate technical replicates were used to calculate the standard deviations of the total peptide intensities for each individual phosphoprotein quantified in this study. A protein-specific normalization factor, **N**, was then generated as follows for each phosphoprotein at each lactation day:

$$N(\text{phosphoprotein } x, \text{ day } y) = \frac{\text{maximum}(\sum [\text{peptide intensities}] \text{ all days})}{\sum [\text{peptide intensities}] \text{ day } y}$$

After generating **N** values, all validated phosphopeptide MS/MS spectra were combined into a list. Phosphopeptides that were not validated in each sample were not selected for quantification. Precursor MS scans corresponding to the extracted ion chromatograms from the first four isotopic peaks (i.e. the monoisotopic mass, and the m+1, 2 and 3) of validated phosphopeptides were summed. These raw values were then multiplied by **N** to yield normalized abundances and the errors of each measurement were propagated during this calculation to yield coefficient of variations (CV). All quantitative comparisons are based on the normalized phosphopeptide areas, or NPA. The final measurements are:

$$NPA = \frac{\sum_m^{m+3} ppArea}{N} \pm \sqrt{\left(CV \left(\sum_m^{m+3} ppArea \right) \right)^2 + CV(N)^2}$$

Where the first quotient gives the mean (reported value) and the second is the CV.

RESULTS

Validation of the experimental approach

To validate the quantification strategy outlined above, a standard containing equimolar amounts of a bovine serum albumin (BSA) standard and FQsEEQQQTEDELQDK phosphopeptide from bovine beta-casein was utilized. First, varying amounts of the standard were injected, and a standard curve of the intensity of the FQsEEQQQTEDELQDK phosphopeptide versus the amount injected was calculated. This plot possessed a high linearity (see supplementary Figure 1). The MS intensities of each peptide identified was summed for each point on the standard curve, and the ratio of total BSA peptide signal to total phosphopeptide signal was also determined for each point on the standard curve. The ratio of beta-casein phosphopeptide response to peptide response remained approximately constant, despite varying quantities injected, supporting the normalization approach utilized in this work.

Protein Identification and Phosphorylation site Determination

All proteins identified in this study are listed in Table 1. Values for the total number of peptides identified, % sequence coverage, Spectrum Mill protein score, the total peptide intensity for a given protein, and the standard deviations of the peptide intensity measurements for each protein are also annotated. Proteins identified as phosphorylated in this study are highlighted in the table. In total, 66 proteins and 7 phosphoproteins were identified. The abundant whey proteins lactoferrin, alpha-lactalbumin, and immunoglobulin A were well represented in the peptide nLC-MS fractions. As expected osteopontin, alpha-casein, and beta-casein were the most abundant proteins present in the phosphopeptide fractions.

Low amounts of phosphorylation were also detected in Poly-Ig receptor, beta-1,4-galactosyltransferase, and alpha-lactalbumin, however these phosphopeptides were not observed in all the samples and therefore any potential changes in abundance were not quantified. Notably, alpha-lactalbumin is not annotated as a phosphoprotein in the swiss-prot, phosphosite, or other databases, suggesting this is the first report of its phosphorylation. Chordin-like protein 2 was also identified as phosphorylated, with two novel sites identified in this study. Only a single phosphorylation site on a single protein isoform was discovered previously.¹⁵

Protein Identification and Phosphorylation site Determination

To quantify changes in phosphorylation site occupancy of specific proteins in complex samples, changes in the protein quantities must first be considered. This was achieved via a label-free quantification method. Two commonly used schemes were compared to determine variation in phosphoprotein expression: spectral counting, and total peptide intensity. While spectral counts have been used to compare the relative quantities of different proteins, the goal of comparing a given protein between samples is better suited for a peak area-based quantitation strategy.¹⁶ While this approach will not allow the comparison of different proteins, (i.e. the quantitation of α -casein to β -casein in different samples) it has been shown to yield more reproducible and sensitive results for the relative quantitation of a given protein between samples¹⁶. Upon application of each method to our results, the peptide area-based quantitation was found to be both more reproducible and more sensitive. Furthermore, previously established variations of lactoferrin¹⁷ during this phase of lactation were confirmed via this method.

Following normalization as detailed, alpha-casein, beta-casein, osteopontin, and chordin-like protein 2 were examined in more detail to determine quantitative variations of specific phosphopeptides observed. These phosphoproteins were selected for quantitation because each analysis yielded identifiable phosphopeptides, and a minimum of 5 nonphosphorylated

peptides for normalization purposes. Quantitative variations in site occupancy of specific phosphopeptides and their standard deviations are annotated in Table 2. Two-tailed heteroschedastic student's t-tests were performed utilizing the normalized phosphopeptide intensities to determine the significance of the observed variations between different lactation days. The singly, doubly, and triply marked values correspond to p values of <0.05, <0.01, and <0.001, respectively. The samples with the highest and lowest occupancies are also annotated. The experimentally determined phosphorylation sites are also indicated when applicable, but collision induced dissociation, (CID) fragmentation data were insufficient in several cases to unambiguously determine the sites of phosphorylation. The challenges of utilizing CID for the determination of phosphorylation sites is well summarized in a recent study by Palumbo et al.¹⁸

Changes in Phosphorylation Occupancy of Beta-Casein

Isomeric structures of several phosphopeptides were also observed. For example, extracted ion chromatograms (EICs) corresponding to the monophosphorylated and diphosphorylated peptide ¹⁷ETIESLSSEESITEYK³³ from beta-casein are shown in Figure 1. Triplicates of each EIC are overlaid to demonstrate the precision of both the peak intensities and the retention times. Notably, there are two resolved isomers of the monophosphorylated phosphopeptide, and only one of the diphosphorylated analog. The presence of two isomers of the monophosphorylated ¹⁷ETIESLSSEESITEYK³³ peptide suggests that there are two separate phosphorylation sites that may be phosphorylated initially. This is verified by careful examination of the MS/MS spectra of the monophosphorylated isomers. The preferred phosphorylation order has previously been shown to be Ser24 > Ser25 > Ser23 > Ser21 > Thr18^{12, 19}, utilizing a combination of 2D gels and tandem mass spectrometry. Combining LC and MS/MS data in the current study suggests however that the phosphorylation is not strictly sequential and that the preference for the initial Ser24 and Ser25 phosphorylation is approximately 2:1. Alpha-casein is known to be phosphorylated by the mammary gland casein kinase, (MGCK) which acts on amino acid sequences of (S/T)-X-(D/E/s/t). It is also possible that the strict phosphorylation order observed previously is followed, and the variation of the monophosphorylated isomer is due to differences in phosphatase expression during these time points. In this study, isoforms corresponding to 0, 1, and 2 phosphates were observed. In certain instances, the sites of phosphorylation could be determined via CID.

Changes in Phosphorylation Occupancy of Alpha-Casein

In alpha-casein, phosphorylation sites are localized in two regions, covered by two tryptic peptides. The quantitative behaviors of these two regions are shown separately, in Figure 2a and 2b. In each case, normalized EICs are overlaid in triplicate. Figure 2a shows the behavior of the phosphopeptide ²⁷LQNPSESSEPIPLESR⁴², with mono-, di-, and tri- phosphorylated versions of the peptide shown. Isomers are observed for the monophosphorylated form only. Despite little change in the total abundance of the predominant monophosphorylated form of this phosphopeptide, the isomer ratio varies from approximately 3:1 at day 2 to approximately 3:2 for all later time points. The diphosphorylated and triphosphorylated isoforms show no significant changes in abundance. The quantitative behavior of the ⁸³MESSISSSEEMSLSK⁹⁸ region of alpha-casein was also determined, and is annotated in Table 2, along with the other phosphopeptides analyzed. This region has two potential primary phosphorylation sites for each of the MGCK and the casein kinase II kinases. The exact sites of phosphorylation could not be definitively determined in this study, but a single isomer of the mono- and diphosphorylated versions of this peptide were observed. Previous work suggests that the primary phosphorylation occurs at Ser90.¹³ Minimal quantitative variations were observed.

Changes in Phosphorylation Occupancy of Osteopontin

Osteopontin is an analytically challenging protein, as it is extensively phosphorylated, glycosylated, and contains a large region spanning approximately 35% of the protein sequence without a single tryptic cleavage site. Two N-glycosylation sites, five O-glycosylation sites, and thirty-six phosphorylation sites have been previously determined²⁰. As shown in Figure 3a, the peptide ¹⁷⁶RPDIQYPDATDEDITSHMESEELNGAYK²⁰³ is present in both mono- and diphosphorylated forms. While the monophosphorylated form exhibits a single chromatographically resolved isomer, there are three for the diphosphorylated analog. Compellingly, the most abundant diphosphorylated isomer demonstrates a highly reproducible 4-fold difference between day 5 and day 10 of lactation. The second most abundant isomer shows a 2-fold difference between day 5 and day 2. There are four serine and threonine residues in this region, and three of have been shown to be phosphorylated (Thr185, Ser191 and Ser195)²⁰. For a diphosphorylated peptide with three possible phosphorylation sites, three isomers are expected, as verified by the presence of three chromatographic peaks. In this region, day five is the least occupied time point for both the mono- and diphosphorylated phosphoforms.

Compellingly, the separate regions of OPN demonstrate disparate changes in phosphorylation occupancy. Shown in Figure 3b are the normalized EICs of the c-terminal phosphopeptide ³⁰⁰FRISHELDSASSEVN³¹⁴. Mono- and diphosphorylated analogs were observed for this region as well, and in each case day seventeen was the least occupied time point. Three to four-fold occupancy differences were observed between day seventeen and day twenty-nine. Another peptide, ²⁵⁰ANDESNEHSDVIDSQELSK²⁶⁸ displays similar a phosphorylation pattern, yet observed changes in this region of OPN were only 2-fold, as seen in Figure 3c. The remaining OPN regions that were quantified are summarized in Table 2. There appears to be very little change in the overall phosphorylation of OPN on the whole, yet significant changes for many of the sites observed.

DISCUSSION

Tracking relative changes in protein phosphorylation of milk proteins is especially difficult because the protein amounts are known to vary during lactation. Therefore, a normalization scheme was implemented to correct for changes in protein expression. The total peptide intensity from each protein was utilized as a proxy for changes in protein expression. The coefficient of variations for this method after three replicate analyses were comparable to quantitation studies that utilize isotopically labeled peptides; however this method has an advantage in that it does not require expensive isotopic labeling reagents, unlike the SILAC²¹ or ICAT²² approaches. Another advantage of using a peptide-level normalization strategy is accounting for potential differences in digestion efficiency between samples. Despite the best efforts to achieve a reproducible digestion, there is always potential for variation in the digestion efficiency. A peptide-level normalization accounts for this variation, since peptides and phosphopeptides are generated simultaneously. The reproducibility afforded by this method is likely a combination of automating the enrichment process and minimizing sample handling.

As expected, the normalization scheme mainly decreased the magnitude of the observed changes in protein phosphorylation (supplementary figure 2); thus, omitting the normalization would have overestimated the relative changes in phosphorylation. This result has implications for other label-free phosphorylation quantification approaches. If determination of the relative amount of site occupancy is the goal, then variations of both protein quantity and digestion efficiency between samples must be taken into consideration. The normalization scheme developed accounts for both of these changes. The precision of these measurements is also comparable to the other quantitative approaches, with 46% of all quantified phosphopeptides

having less than 10% coefficient of variations, and 85% having less than 30% coefficient of variations in this study.

It should be noted that the results of this study are preliminary, as the samples were provided by a single individual. A larger study must be performed before generalizations may be made regarding quantitative changes of milk phosphorylation in the population. This study does, however, suggest that human milk is an interesting target for future experiments, and presents an effective methodology to carry out those experiments. Possible biological implications of this work are discussed below.

While there were changes in total protein phosphorylation during lactation for some phosphoproteins, in other instances there was very little protein-level phosphorylation variation. OPN is extensively phosphorylated and the sites vary in occupancy to such a degree that one might expect significant protein-level variation. Instead, individual phosphorylation sites were either up- or down-regulated in a contrary manner to effect substantial local phosphorylation variation, but little change in the overall phosphorylation of OPN. Little data exists to determine any potential changes in the function between the hundreds of possible phosphoforms of this protein; therefore the functional implications of these changes are unknown. OPN research to date has shown that it is a multifunctional protein, implicated in cell migration, mineralization, cellular proliferation, and osteoblast formation.²³⁻²⁹ OPN has been shown to exhibit both a pro- and an anti-inflammatory function depending on the location in the body.²⁴ Therefore, it is possible that the role of OPN also changes during the course of lactation the change could be mediated by dynamic phosphorylation. Given the many biological functions that OPN possesses throughout the body and the extent of phosphorylation present on the protein, phosphorylation likely regulates function to a large extent.

As our approach utilized a bottom-up approach, changes in OPN phosphorylation were localized to individual phosphopeptides containing up to three phosphorylation sites, therefore changes in individual regions were identifiable. With a protein that is as extensively phosphorylated as OPN, a top-down analytical method would have greatly complicated elucidation of the site-specific dynamic phosphorylation observed.

The phosphorylation sites of alpha-casein are localized on two separate tryptic peptides. One of these regions shows little to no variation in the samples analyzed in this study. The other demonstrates quantitative variations of up to two fold. One might expect this would show a significant change in the overall phosphorylation intensity as measured by MS. However, the intensity of the variable phosphopeptides is approximately an order of magnitude lower than those that are unchanging, and subsequently no significant protein-level differences are observed. A previous study suggests that the difference in intensity between the two phosphorylation regions results from a site occupation difference between these regions, rather than differences in ionization efficiency.¹³

While the determination of the relative quantitative differences in phosphorylation occupancy was the primary goal of this study, identification of previously unreported phosphorylation sites was also achieved. In addition to the known phosphoproteins discussed previously, minor phosphorylation was also detected in this study on alpha-lactalbumin, a highly abundant whey protein. The phosphorylation sites detected in these analyses, Ser95 and Thr105, are consistent with the known specificity of MGCK. As the MGCK is the most active kinase in the mammary gland, and considering alpha-lactalbumin possesses the known motif required, it is likely that the trace level of phosphorylation detected here is carried out by the MGCK. In addition, bovine alpha-lactalbumin is phosphorylated by the casein kinase.³⁰ This is the first known report of enzymatic phosphorylation of this abundant human whey protein. Functionally, alpha-lactalbumin is known to modulate the specificity of the beta-1,4-galactosyltransferase to enable

the production of lactose in the mammary epithelial cells. Beta 1-4 galactosyl transferase was also identified as phosphorylated in this study. Alpha-lactalbumin can also induce cellular apoptosis upon formation of a complex with fatty acids during digestion³¹.

This is the first report of the characterization of CHRDL2 phosphorylation in human milk. Interestingly, CHRDL2 possesses three von Willebrand factor type C repeats, suggesting that it is potentially secreted as a multiprotein complex. Regardless of secretion state, CHRDL2 has been implicated in several biological processes, including myoblast and osteoblast maturation, bone morphogenic protein inhibition, and tumor angiogenesis.³² CHRDL2 is known to be highly expressed in tumors and epithelial cells.³³ Its role in both milk and the normal mammary gland, however, is unreported to date.

CONCLUSIONS

In this study, a label-free LC-MS/MS quantification method was applied to the study of human milk phosphorylation from an individual during the first month of lactation. This is the first known report of relative quantitation of human milk proteins during lactation. As the expression levels of milk proteins are known to vary during the course of lactation, a normalization strategy based on total peptide signal was developed and incorporated into the quantitative method to elucidate changes in phosphorylation site occupancy. The precision of the results obtained in this study were comparable to published results utilizing expensive isotopic labeling reagents.

Very few studies have been performed to elucidate the phosphoproteome of human milk and substantial work remains to expand our understanding of milk protein phosphorylation to include low abundance phosphoproteins. The abundant caseins and osteopontin are the best characterized phosphoproteins to date. This is the first known report of alpha-lactalbumin phosphorylation, a highly abundant and well-studied whey protein, yet the trace levels of phosphorylation identified were previously unknown. In addition, this is the first known study to characterize CHRDL2 phosphorylation in human milk.

Although this approach did not utilize many of the protein fractionation strategies that site-directed phosphoproteomic studies employ, novel sites of phosphorylation were nevertheless determined for a few milk proteins. A more extensive sample fractionation would likely facilitate the identification of additional novel phosphorylation sites in human milk proteins. However, extensive sample fractionation would also complicate the quantitative determination of phosphorylation occupancy as determined in this study.

In addition, it should be noted that the enrichment strategy used is has been shown to bias the phosphopeptides observed. Titanium dioxide has been shown to preferentially enrich for singly phosphorylated phosphopeptides and serine and threonine phosphorylated phosphopeptides³⁴. Other enrichment strategies each have their biases as well. Phosphotyrosine antibodies are specific to phosphotyrosine residues, which is critical as these residues are much lower in abundance than phosphoserine or phosphothreonine residues. In addition, immobilized metal affinity chromatography has a higher affinity to multiply phosphorylated phosphopeptides³⁵. Future work must consider the enrichment strategy a vital component of the research plan, as it will influence the information gained. For example, human milk proteins are extensively phosphorylated on serine and threonine residues, and a different strategy would be required to characterize phosphotyrosine containing peptides.

While many phosphopeptides demonstrate dynamic occupancy rates during the first month of lactation it is unclear at this time what the observed changes may signify biologically. Continuing this study with a larger cohort will lead to a better understanding as to the extent of quantitative changes in the population at large. The existence of dynamic phosphorylation in early lactation potentially represents a biological adjustment to meet the needs of the infant.

Understanding how these specific components change during lactation may lend critical insight into early infant development.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Bibliography

1. Mohammed S, Kraiczek K, Pinkse MW, Lemeer S, Benshop JJ, Heck AJ. Chip-Based Enrichment and NanoLC-MS/MS Analysis of Phosphopeptides from Whole Lysates. *Journal of proteome research* 2008;7(4):1565–71. [PubMed: 18307298]
2. Boehm G, Stahl B. Oligosaccharides from milk. *J Nutr* 2007;137(3 Suppl 2):847S–9S. [PubMed: 17311985]
3. Lonnerdal B. Nutritional and physiologic significance of human milk proteins. *Am J Clin Nutr* 2003;77(6):1537S–1543S. [PubMed: 12812151]
4. Hendrixson DR, Qiu J, Shewry SC, Fink DL, Petty S, Baker EN, Plaut AG, St Geme JW 3rd. Human milk lactoferrin is a serine protease that cleaves Haemophilus surface proteins at arginine-rich sites. *Mol Microbiol* 2003;47(3):607–17. [PubMed: 12535064]
5. Olivecrona T, Hernell O. Human milk lipases and their possible role in fat digestion. *Pediatr Padol* 1976;11(4):600–4. [PubMed: 980524]
6. Picariello G, Ferranti P, Fierro O, Mamone G, Caira S, Di Luccia A, Monica S, Addeo F. Peptides surviving the simulated gastrointestinal digestion of milk proteins: Biological and toxicological implications. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2009
7. Lonnerdal B. Breast milk: a truly functional food. *Nutrition* 2000;16(7-8):509–11. [PubMed: 10906538]
8. Ward RE, Ninonuevo M, Mills DA, Lebrilla CB, German JB. In vitro fermentation of breast milk oligosaccharides by *Bifidobacterium infantis* and *Lactobacillus gasseri*. *Appl Environ Microbiol* 2006;72(6):4497–9. [PubMed: 16751577]
9. Hanson LA, Korotkova M, Telford E. Breast-feeding, infant formulas, and the immune system. *Ann Allergy Asthma Immunol* 2003;90(6 Suppl 3):59–63. [PubMed: 12839115]
10. Isaacs EB, Fischl BR, Quinn BT, Chong WK, Gadian DG, Lucas A. Impact of breast milk on IQ, brain size and white matter development. *Pediatr Res*. 2009
11. Kunz C, Lonnerdal B. Re-evaluation of the whey protein/casein ratio of human milk. *Acta Paediatr* 1992;81(2):107–12. [PubMed: 1515752]
12. Poth AG, Deeth HC, Alewood PF, Holland JW. Analysis of the human casein phosphoproteome by 2-D electrophoresis and MALDI-TOF/TOF MS reveals new phosphoforms. *Journal of proteome research* 2008;7(11):5017–27. [PubMed: 18847231]
13. Kjeldsen F, Savitski MM, Nielsen ML, Shi L, Zubarev RA. On studying protein phosphorylation patterns using bottom-up LC-MS/MS: the case of human alpha-casein. *Analyst* 2007;132(8):768–76. [PubMed: 17646876]
14. Sorensen ES, Moller L, Vinther M, Petersen TE, Rasmussen LK. The phosphorylation pattern of human alphas1-casein is markedly different from the ruminant species. *Eur J Biochem* 2003;270(17):3651–5. [PubMed: 12919330]
15. Zhou W, Ross MM, Tessitore A, Ornstein D, Vanmeter A, Liotta LA, Petricoin EF 3rd. An initial characterization of the serum phosphoproteome. *J Proteome Res* 2009;8(12):5523–31. [PubMed: 19824718]
16. Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, Sevinisky JR, Resing KA, Ahn NG. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. *Mol Cell Proteomics* 2005;4(10):1487–502. [PubMed: 15979981]
17. Hirai Y, Kawakata N, Satoh K, Ikeda Y, Hisayasu S, Orimo H, Yoshino Y. Concentrations of lactoferrin and iron in human milk at different stages of lactation. *J Nutr Sci Vitaminol (Tokyo)* 1990;36(6):531–44. [PubMed: 2097325]

18. Palumbo AM, Reid GE. Evaluation of gas-phase rearrangement and competing fragmentation reactions on protein phosphorylation site assignment using collision induced dissociation-MS/MS and MS3. *Anal Chem* 2008;80(24):9735–47. [PubMed: 19012417]
19. Greenberg R, Groves ML, Dower HJ. Human beta-casein. Amino acid sequence and identification of phosphorylation sites. *The Journal of biological chemistry* 1984;259(8):5132–8. [PubMed: 6715339]
20. Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sorensen ES. Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. *Biochem J* 2005;390(Pt 1):285–92. [PubMed: 15869464]
21. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. *Mol Cell Proteomics* 2002;1(5):376–86. [PubMed: 12118079]
22. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. *Nat Biotechnol* 1999;17(10):994–9. [PubMed: 10504701]
23. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, Kundu GC. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. *Curr Mol Med* 2006;6(8):819–30. [PubMed: 17168734]
24. Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. *Curr Atheroscler Rep* 2009;11(3):206–13. [PubMed: 19361352]
25. Standal T, Borset M, Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. *Exp Oncol* 2004;26(3):179–84. [PubMed: 15494684]
26. Sodek J, Batista Da Silva AP, Zohar R. Osteopontin and mucosal protection. *J Dent Res* 2006;85(5):404–15. [PubMed: 16632752]
27. Agnholt J, Kelsen J, Schack L, Hvas CL, Dahlerup JF, Sorensen ES. Osteopontin, a protein with cytokine-like properties, is associated with inflammation in Crohn's disease. *Scand J Immunol* 2007;65(5):453–60. [PubMed: 17444956]
28. Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. *Toxicol Sci* 2008;103(1):4–13. [PubMed: 17890765]
29. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. *Cytokine Growth Factor Rev* 2008;19(5-6):333–45. [PubMed: 18952487]
30. Bingham EW, Parris N, Farrell HM Jr. Phosphorylation of beta-casein and alpha-lactalbumin by casein kinase from lactating bovine mammary gland. *J Dairy Sci* 1988;71(2):324–36. [PubMed: 3164001]
31. Svensson M, Hakansson A, Mossberg AK, Linse S, Svanborg C. Conversion of alpha-lactalbumin to a protein inducing apoptosis. *Proc Natl Acad Sci U S A* 2000;97(8):4221–6. [PubMed: 10760289]
32. Oren A, Toporik A, Biton S, Almogly N, Eshel D, Bernstein J, Savitsky K, Rotman G. hCHL2, a novel chordin-related gene, displays differential expression and complex alternative splicing in human tissues and during myoblast and osteoblast maturation. *Gene* 2004;331:17–31. [PubMed: 15094188]
33. Wu I, Moses MA. BNF-1, a novel gene encoding a putative extracellular matrix protein, is overexpressed in tumor tissues. *Gene* 2003;311:105–10. [PubMed: 12853144]
34. Sugiyama N, Masuda T, Shinoda K, Nakamura A, Tomita M, Ishihama Y. Phosphopeptide enrichment by aliphatic hydroxy acid-modified metal oxide chromatography for nano-LC-MS/MS in proteomics applications. *Mol Cell Proteomics* 2007;6(6):1103–9. [PubMed: 17322306]
35. Sugiyama N, Masuda T, Shinoda K, Nakamura A, Tomita M, Ishihama Y. Phosphopeptide enrichment by aliphatic hydroxy acid-modified metal oxide chromatography for nano-LCMS/MS in proteomics applications. *Mol. Cell. Proteomics* 2007;6:1103–1109. [PubMed: 17322306]

FIGURE 1.

Overlaid, triplicate extracted ion chromatograms of mono- (1a) or di- (1b) phosphorylated peptide ETIESLSSSEESITEYK from beta-casein. Isomeric separation of the monophosphorylated peptide is observed. The more abundant peak eluting at 29.8 minutes corresponds to ETIESLSSsEESITEYK, (pSer25). Only a single isomer of the diphosphorylated peptide is observed.

FIGURE 2.

Overlaid triplicate extracted ion chromatograms of singly, doubly and triply phosphorylated LQNPSESSEPIPLESR peptide from alpha-casein. Isomeric separation is apparent for the monophosphorylated peptide only. Minor, yet significant, differences are observed. The largest relative change occurs between days 2 and 5 of the monophosphorylated isomer eluting at 26.4 minutes, corresponding to LQNPSEsSEPIPLESR (pSer33), while the major species eluting at 25.9 minutes is LQNPSESSEPIPLEsR (pSer41).

FIGURE 3.

Overlaid triplicate extracted ion chromatograms of three distinct regions of phosphorylation of osteopontin. In **A**, RPDIQYPDATDEDITSHMESEELNGAYK with one and two phosphates is examined. Section **B** corresponds to the C-terminal region FRISHELDASSEVN, and section **C** corresponds to ANDESNEHSDVIDSQELSK. For both **A** and **B**, the monophosphorylated peptides give a single isomer and highly dynamic occupancies, while the diphosphorylated peptides vary in disparate manners. In **C**, however, the monophosphopeptide has a single isomer, while the diphosphorylated form exhibits two isomers which vary similarly.

TABLE 1

A summary of proteins identified via nLC-MS/MS analyses. Protein Name, molecular weight in kilodaltons (MW), Accession Number, percent amino acid coverage, and the number of unique peptides are annotated. Phosphoproteins identified in this study are written in bold and underlined.

Protein Name	Accession Number	% AA Coverage	# unique peptides	Score
Lactotransferrin	P02788	88	91	1896
Serum albumin	P02768	85	68	1215
<u>Polymeric immunoglobulin receptor</u>	P01833	52	48	879
Bile salt-activated lipase	P19835	46	40	745
Xanthine dehydrogenase/oxidase	P47989	31	35	604
<u>Alpha-lactalbumin</u>	P00709	51	19	403
Ig alpha-1 chain C region	P01876	76	19	387
Clusterin	P10909	34	17	296
<u>Osteopontin</u>	P10451	57	17	255
Immunoglobulin J chain	P01591	78	13	250
<u>Chordin-like protein 2</u>	Q6WN34	41	13	248
<u>Alpha-S1-casein OS</u>	P47710	58	13	244
Leucine-rich alpha-2-glycoprotein	P02750	46	13	242
Adipophilin	Q99541	43	14	242
Butyrophilin subfamily 1 member A1	Q13410	32	15	234
Alpha-1-antitrypsin	P01009	32	13	232
Fatty acid-binding protein, heart	P05413	83	13	232
Monocyte differentiation antigen CD14	P08571	48	13	217
Ig lambda chain C regions	P01842	97	11	208
Lactadherin	Q08431	42	12	204
<u>Beta-casein</u>	P05814	82	11	203
Kappa-casein	P07498	56	11	198
Ig kappa chain C region	P01834	89	9	193
Apolipoprotein A-I	P02647	50	13	187
Serotransferrin	P02787	22	12	185
Zinc-alpha-2-glycoprotein	P25311	37	9	166
Haptoglobin	P00738	30	9	160
Macrophage mannose receptor 1-like protein 1	Q5VSK2	7	10	145
Ig mu chain C region	P01871	28	9	142
Tenascin	P24821	6	8	137
Alpha-1-antichymotrypsin	P01011	18	9	134
Fatty acid synthase	P49327	4	8	124
<u>Beta-1,4-galactosyltransferase 1</u>	P15291	30	7	122
Complement C4-B	P0C0L5	8	8	119
Alpha-1-acid glycoprotein 1	P02763	25	5	96
Lipoprotein lipase	P06858	22	6	91
Actin, cytoplasmic 2	P63261	24	6	90
Mucin-4	Q99102	2	5	88

Protein Name	Accession Number	% AA Coverage	# unique peptides	Score
Lysozyme C	P61626	43	5	87
Alpha-enolase	P06733	20	6	84
Ig gamma-1 chain C region	P01857	21	4	81
Beta-2-microglobulin	P61769	37	4	65
Ig kappa chain V-III region GOL	P04206	36	3	58
Complement C3	P01024	2	3	57
Alpha-1B-glycoprotein	P04217	9	3	46
Galectin-3-binding protein	Q08380	7	3	40
Peptidyl-prolyl cis-trans isomerase A	P62937	15	2	39
Sulfhydryl oxidase I	O00391	4	2	38
Ig lambda chain V-III region LOI	P80748	21	2	37
Ig kappa chain V-I region WEA	P01610	21	2	35
RB1-inducible coiled-coil protein 1	Q8TDY2	0	3	35
Mucin-1	P15941	1	2	34
Ig heavy chain V-III region BRO	P01766	19	2	32
Apolipoprotein A-II	P02652	42	2	32
Proactivator polypeptide	P07602	4	2	31
Ig heavy chain V-III region WAS	P01776	19	2	30
Ubiquitin	P62988	27	2	30
UTP--glucose-1-phosphate uridylyltransferase	Q16851	4	2	28
Myosin-VI	Q9UM54	3	3	27
Insulin-like growth factor-binding protein 2	P18065	10	2	26
Ig lambda chain V-I region WAH	P04208	16	2	26
Sclerostin domain-containing protein 1	Q6X4U4	18	2	25
Nucleobindin-2	P80303	7	2	23
Selenium-binding protein 1	Q13228	4	2	21
Uncharacterized protein KIAA0467	Q5T011	0	2	21
Ig heavy chain V-III region GAL	P01781	13	2	20

TABLE 2

A summary of the 44 unique phosphopeptides quantified in these studies. All quantitative values are reported as the mean of normalized triplicate analyses, along with relative standard deviations (RSD) for each lactation day. Two-tailed, heteroschedastic t-tests were performed, and the significance level between the maximum and minimum quantitative values are also annotated. Singly, doubly, or triply asterisked entries correspond to significance levels of $p < 0.05$, $p < 0.01$, and $p < 0.001$ respectively.

Protein Name	#Phos	Swiss-Prot	Var. Site	Peptide Sequence	RT	m/z	score	FOLD-change	sig-level	Max Day	Min Day	D2 Mean	D2 RSD	D5 Mean	D5 RSD	D10 Mean	D10 RSD	D17 Mean	D17 RSD	D29 Mean	D29 RSD
ACAS	1	P47710		(K)MESSISSSEEMSLSK(C)	23.46	600.2407	20.6	1.39	**	2	29	1.13E+06	7	9.77E+05	11	1.00E+06	8	8.70E+05	2	8.08E+05	6
ACAS	2	P47710		(K)MESSISSSEEMSLSK(C)	23.83	939.841	15.5	1.49	***	2	29	4.50E+05	6	3.82E+05	11	3.65E+05	8	3.24E+05	5	3.02E+05	4
ACAS	1	P47710	M-->m	(K)MESSISSSEEMSLSK(C)	20.56	907.8385	19.0	1.73	***	2	17	3.30E+05	8	2.66E+05	11	2.33E+05	8	1.91E+05	3	2.27E+05	3
ACAS	1	P47710	M-->m	(K)MESSISSSEEMSLSK(C)	21.81	907.8508	20.9	1.33	**	2	17	7.43E+05	7	6.93E+05	11	6.12E+05	7	5.57E+05	4	5.92E+05	5
ACAS	1	P47710	M-->m	(K)MESSISSSEEMSLSK(C)	23.34	605.5716	21.1	1.47	*	5	17	2.83E+05	11	2.92E+05	20	2.54E+05	12	1.99E+05	9	2.00E+05	21
ACAS	1	P47710	41	(R)LQNPFSESSEPIPLEsR(E)	25.87	621.6178	19.1	1.41	*	2	29	3.42E+07	13	2.88E+07	18	2.95E+07	10	2.61E+07	6	2.44E+07	15
ACAS	1	P47710	33	(R)LQNPFSESEPIPLEsR(E)	26.43	621.6116	23.2	2.35	**	5	2	9.34E+06	15	2.19E+07	15	1.55E+07	13	1.41E+07	4	1.30E+07	15
ACAS	2	P47710		(R)LQNPFSESSEPIPLEsR(E)	26.67	971.897	20.4	1.46	*	29	5	1.98E+07	16	1.52E+07	27	1.65E+07	20	2.02E+07	5	2.23E+07	9
ACAS	3	P47710	31,33,41	(R)LQNPFsESSEPIPLEsR(E)	26.68	1011.8905	12.9	1.34	**	29	10	9.28E+05	8	8.92E+05	14	8.33E+05	8	1.03E+06	7	1.12E+06	4
BCAS	1	P05814		(R)ETIESLSSEESITEYK(Q)	28.06	671.2771	12.4	2.71	**	29	10	2.26E+05	17	2.47E+05	20	2.16E+05	15	3.02E+05	22	5.85E+05	28
BCAS	1	P05814	25	(R)ETIESLSSEESITEYK(Q)	29.81	1006.4277	13.8	3.06	**	29	5	3.22E+05	16	3.04E+05	18	3.76E+05	17	8.54E+05	19	9.32E+05	20
BCAS	2	P05814	24,25	(R)ETIESLSsEEsSITEYK(Q)	28.86	1046.3926	19.3	3.11	**	17	5	1.04E+06	16	5.58E+05	18	1.17E+06	17	1.74E+06	20	1.46E+06	20
CHRD12	1	4	182	(K)DEASEQsDEEDSVQSLHGVR(H)	21.63	766.29	23.1	2.51	**	2	17	2.18E+06	19	9.85E+05	37	1.29E+06	39	8.70E+05	19	1.53E+06	24
CHRD12	1	Q6WN34	182	(K)DEASEQsDEEDSVQsLHGVRHPQDPcSSDAGR(K)	20.43	901.8612	12.2	2.67	**	2	17	4.59E+05	18	2.31E+05	37	2.96E+05	39	1.72E+05	19	3.45E+05	24
CHRD12	2	4	179,182	(K)DEAsEQsDEEDSVQSLHGVR(H)	22.45	792.964	13.4	2.19	**	2	5	2.64E+05	17	1.21E+05	35	1.85E+05	39	1.34E+05	19	2.15E+05	29
CHRD12	2	Q6WN34	179,182	(K)DEAsEQsDEEDSVQsLHGVRHPQDPcSSDAGR(K)	21.05	737.6853	15.8	2.24	**	2	17	2.43E+05	18	1.32E+05	36	1.77E+05	39	1.09E+05	19	2.06E+05	30
OST	2	P10451	62,63	(K)QNLLAPQNAVsEEtNDFK(Q)	29.79	1132.956	12.2	3.54	***	29	5	1.05E+05	19	8.91E+04	41	1.34E+05	20	2.83E+05	6	3.15E+05	6
OST	2	P10451		(K)QNLLAPQNAVsEEtNDFKQETLPSK(S)	30.22	1016.7695	13.1	1.74	***	2	5	1.40E+05	7	8.05E+04	6	9.43E+04	8	9.54E+04	7	8.30E+04	5
OST	1	P10451		(R)RPDIQYPDA tDEdITsHMESEELNGAYK(A)	30.37	826.8363	15.2	2.15	***	2	17	4.81E+06	11	2.23E+06	8	3.60E+06	9	2.23E+06	5	2.71E+06	5
OST	2	P10451		(R)RPDIQYPDA dEDITsHMESEELNGAYK(A)	30.58	846.827	10.4	2.01	***	2	5	1.47E+06	5	7.32E+05	14	1.16E+06	4	1.07E+06	6	1.28E+06	6
OST	2	P10451		(R)RPDIQYPDA dEDITsHMESEELNGAYK(A)	31.70	846.827	16.7	3.90	***	17	5	1.66E+06	4	7.15E+05	9	2.71E+06	12	2.79E+06	8	1.97E+06	6
OST	3	P10451		(R)RPDIQYPDA dEDITsHMEsEElNGAYK(A)	31.76	866.8169	15.6	7.42	***	17	5	7.34E+05	4	2.42E+05	6	1.19E+06	13	1.79E+06	5	9.46E+05	11
OST	1	P10451		(K)AIPVAQDLNAPsDWDSRGK(D)	29.22	707.3255	12.2	1.88	***	5	17	2.71E+06	15	3.80E+06	7	2.93E+06	3	2.02E+06	5	3.26E+06	8

Protein Name	#Phos	Swiss-Prot	Var. Site	Peptide Sequence	RT	m/z	score	FOLD-change	sig. level	Max Day	Min Day	D2 Mean	D2 RSD	D5 Mean	D5 RSD	D10 Mean	D10 RSD	D17 Mean	D17 RSD	D29 Mean	D29 RSD
OST	1	P10451	219	(K)AIPVAQDLNAPSDWDsR(G)	31.27	967.9333	23.1	1.96	**	10	29	1.71E+07	9	1.48E+07	16	1.99E+07	15	1.40E+07	9	1.02E+07	7
OST	2	P10451			31.98	1007.8992	8.2	5.38	***	10	2	2.60E+04	39	3.49E+04	20	1.40E+05	10	7.87E+04	20	6.84E+04	22
OST	2	P10451		(R)GKDsYETSQLDDQsAETHSHK(Q)	16.05	631.4949	9.1	1.30	--	29	17	7.09E+05	9	5.57E+05	8	5.77E+05	8	5.49E+05	6	7.11E+05	19
OST	2	P10451			15.07	724.2851	18.5	1.59	**	2	17	1.55E+06	7	1.05E+06	12	1.26E+06	17	9.77E+05	14	1.46E+06	6
OST	3	P10451		(K)AIPVAQDLNAPsDWDsRGKDsYETSQLDDQsAETHSHK(Q)	28.92	888.5433	13.8	1.96	*	10	29	3.81E+06	9	2.47E+06	19	4.19E+06	22	3.42E+06	13	2.14E+06	17
OST	1	P10451	263	(K)ANDESNEHSDVIDsQELsK(V)	20.09	732.9663	20.2	2.09	***	5	17	2.27E+05	8	4.25E+05	10	3.11E+05	9	2.03E+05	5	3.70E+05	8
OST	1	P10451	254	(K)ANDEsNEHSDVIDsQELsK(V)	20.74	732.9626	18.4	2.03	***	5	17	4.56E+05	5	7.19E+05	7	5.29E+05	4	3.54E+05	5	6.59E+05	7
OST	2	P10451		(K)ANDEsNEHSDVIDsQELsK(V)	21.04	759.6217	19.6	1.35	***	10	17	2.35E+06	3	2.14E+06	6	2.38E+06	3	1.77E+06	4	2.32E+06	5
OST	1	P10451	254	(R)KANDESNEHsDVIDsQELsK(V)	19.28	581.9981	10.7	3.09	--	29	2	2.61E+04	66	4.12E+04	82	5.56E+04	120	5.00E+04	80	8.07E+04	93
OST	2	P10451	254, 263	(R)KANDESNEHsDVIDsQELsK(V)	19.67	802.3174	15.0	1.58	--	29	5	1.40E+06	49	1.24E+06	63	1.60E+06	58	1.48E+06	48	1.96E+06	38
OST	3	P10451	254, 258, 263	(R)KANDEsNEHsDVIDsQELsK(V)	19.85	828.9763	10.9	3.01	***	29	2	1.57E+05	24	2.28E+05	31	3.43E+05	30	3.44E+05	21	4.72E+05	9
OST	2	P10451	M-->m 275, 280	(R)EFHsHEFHsHEDmLVVDPK(S)	22.11	624.7453	10.5	2.49	***	29	17	3.58E+06	3	4.13E+06	7	2.81E+06	8	2.11E+06	5	5.24E+06	6
OST	2	P10451	275,280	(R)EFHsHEFHsHEDMLVVDPK(S)	24.51	620.7382	9.6	1.46	***	2	17	6.44E+06	5	5.29E+06	6	4.91E+06	4	4.41E+06	5	5.74E+06	7
OST	1	P10451		(R)ISHELDsASSEVN(-)	18.03	734.3083	13.1	3.57	***	10	5	3.86E+04	20	1.23E+04	10	4.40E+04	5	3.41E+04	10	2.83E+04	24
OST	1	P10451		(R)IsHELDSASSEVN(-)	18.88	734.2938	15.1	4.20	--	29	17	2.22E+05	24	3.20E+05	26	1.37E+05	27	7.75E+04	33	3.25E+05	94
OST	2	P10451		(R)IsHELDSASsEVN(-)	18.81	774.2699	10.0	2.70	***	2	5	2.42E+05	3	8.96E+04	35	1.81E+05	20	1.50E+05	23	1.52E+05	81
OST	2	P10451		(R)IsHELDSsASSEVN(-)	19.65	774.2817	9.9	3.02	**	2	17	2.41E+05	18	1.32E+05	73	1.53E+05	61	8.00E+04	51	2.24E+05	38
OST	1	P10451	303	(K)FRISHELDSsSEVN(-)	26.73	590.928	14.2	5.32	***	29	17	6.36E+06	3	1.71E+07	9	6.42E+06	5	3.84E+06	8	2.04E+07	6
OST	2	P10451		(K)FRIsHELDSsASSEVN(-)	25.66	925.8497	9.7	3.32	**	2	5	1.98E+05	15	5.96E+04	30	1.01E+05	18	7.32E+04	8	6.63E+04	8
OST	2	P10451	303+(x)	(K)FRISHELDSsSEVN(-)	26.64	925.8497	10.7	3.74	***	17	5	1.35E+06	20	6.48E+05	7	2.16E+06	9	2.43E+06	5	2.39E+06	12
OST	2	P10451	303+(x)	(K)FRISHELDSsSEVN(-)	27.51	925.8497	10.8	3.35	***	29	17	5.46E+06	6	7.15E+06	5	4.11E+06	4	2.35E+06	6	7.88E+06	10